Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company developing and commercializing ONS-5010/LYTENAVA, the first ophthalmic-specific formulation of bevacizumab, for the intravitreal treatment of retinal diseases — primarily wet AMD — serving retina specialists and ophthalmologists across the EU, UK, and pending US markets.
- Company typePublic
- Founded2015
- HeadquartersIselin, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Outlook Therapeutics does
Outlook Therapeutics (NASDAQ: OTLK) is a biopharmaceutical company developing and commercializing a single ophthalmic asset — ONS-5010/LYTENAVA (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK) — an ophthalmic formulation of the recombinant humanized anti-VEGF monoclonal antibody bevacizumab, delivered via intravitreal injection for the treatment of retinal diseases. The product targets wet age-related macular degeneration (wet AMD) as its lead indication, with diabetic macular edema (DME) and branch retinal vein occlusion (BRVO) as subsequent label-expansion opportunities; LYTENAVA's value proposition rests on being the first ophthalmic-specific bevacizumab formulation, addressing contamination, potency variability, and supply disruptions associated with compounded IV bevacizumab. Manufacturing is centralized with proprietary process controls for sterility, pH, and particulate limits meeting ophthalmic regulatory standards.
The company operates a specialty-pharma commercial model using a direct enterprise field sales force in Europe (deployed through specialty distributors in Germany, UK, and Austria) and a channel-led US go-to-market pending FDA approval — including specialty distribution via Cencora and McKesson, GPO partnerships (SPN, CureScript, OnMark), and a patient services hub. The drug was authorized by the European Commission (May 2024) and UK MHRA (July 2024) with a positive NICE recommendation (December 2024), and commercial launches occurred in Germany and the UK in June 2025 and Austria in 2026. The US BLA has been resubmitted (June 2026) with a PDUFA target action date of July 29, 2026, following a successful FDA Formal Dispute Resolution appeal in May 2026.
Financials reflect a pre-scale single-asset biotech: ~17 employees, FY2025 product revenue of $1.4M from initial European launches, FY2025 net loss of $62.4M (improved from $75.4M), and a series of debt and equity financings in 2025-2026 (Atlas Sciences $18.4M note; multiple H.C. Wainwright-led public and registered direct offerings and an Avondale Capital convertible note) to sustain operations through anticipated US commercialization.
Outlook Therapeutics firmographics
Firmographics- Name
- Outlook Therapeutics
- Legal name
- Outlook Therapeutics, Inc.
- Website
- https://outlooktherapeutics.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Outlook Therapeutics is a biopharmaceutical company developing and commercializing ONS-5010/LYTENAVA, the first ophthalmic-specific formulation of bevacizumab, for the intravitreal treatment of retinal diseases — primarily wet AMD — serving retina specialists and ophthalmologists across the EU, UK, and pending US markets.
- Ownership category
- akta.pro rank
Outlook Therapeutics industry classification
Industry- Product category
- Ophthalmic Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
- akta.pro secondary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where Outlook Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Iselin
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Outlook Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Product Sales (LYTENAVA): Revenue from commercial sales of LYTENAVA (bevacizumab gamma) for wet AMD in European markets. Initial product revenue began June 2025 in Germany and UK, expanded to Austria in 2026. Q2 FY2026 showed approximately 10% sequential decline in European unit sales. Swiss market launch expected in 2027 pending regulatory approval through Mediconsult distribution agreement.
- US Market (Pending FDA Approval): If FDA approves ONS-5010/LYTENAVA, the company expects to generate US product revenue through specialty distribution channels, GPO contracts, and direct provider engagement. PDUFA target action date set for July 29, 2026.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Pricing not publicly disclosed |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Outlook Therapeutics product offering
Product offeringCore offering
Outlook Therapeutics develops and commercializes ONS-5010/LYTENAVA (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), an ophthalmic formulation of the anti-VEGF monoclonal antibody bevacizumab, administered via intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). The product has received European Commission and MHRA Marketing Authorization and is under FDA review in the United States.
Product overview
Outlook Therapeutics is a biopharmaceutical company with a single focused product: ONS-5010/LYTENAVA (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK). This is an ophthalmic formulation of the anti-VEGF monoclonal antibody bevacizumab, positioned to become the first approved ophthalmic formulation of bevacizumab for retinal disease indications. The product is administered via intravitreal injection and targets VEGF to reduce endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina. The company operates with a single-product portfolio: ONS-5010/LYTENAVA is approved and commercially launched in Europe (Germany, Austria) and the UK, while the US BLA remains under FDA review with a PDUFA target action date of July 29, 2026.
Differentiator
Problem solved
Functional benefit
Brands
- LYTENAVA: ONS-5010/LYTENAVA is an ophthalmic formulation of bevacizumab (bevacizumab-vikg in the US, bevacizumab gamma in EU/UK) for the treatment of wet age-related macular degeneration (wet AMD). It is a recombinant humanized monoclonal antibody that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF's biologic activity.
Products and services
- ONS-5010 / LYTENAVA (bevacizumab-vikg / bevacizumab gamma) Ophthalmic formulation of bevacizumab (a recombinant humanized anti-VEGF monoclonal antibody) administered via intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), with additional indications under development for diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). Approved in EU and UK; under FDA review in the United States.
Companies that use Outlook Therapeutics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Outlook Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Outlook Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Mediconsult AGcoreExclusive commercial distribution agreement with Mediconsult AG for Switzerland market. Mediconsult holds exclusive rights to market, import, distribute, and commercialize LYTENAVA (bevacizumab gamma) for wet AMD treatment in Switzerland. Mediconsult is responsible for regulatory activities including seeking Marketing Authorization in Switzerland. Outlook Therapeutics retains manufacturing, product supply, and intellectual property responsibilities. Expected Swiss market launch in 2027 pending regulatory approval.
Scale indicators12 records
Recent moves6 records
Expansion highlights5 records
Outlook Therapeutics competitors and assessment
Company assessmentDirect peers
- Regeneron Pharmaceuticals: Regeneron markets Eylea (aflibercept), the leading FDA-approved anti-VEGF therapy for wet AMD. As the dominant premium anti-VEGF product targeting the same wet AMD patient population, it is the most direct competitor Outlook would face on US launch of LYTENAVA.
- Astellas Pharma (Iveric Bio): Through its acquisition of Iveric Bio, Astellas markets Izervay (avacincaptad pegol) for geographic atrophy and competes in the retinal disease space with similar specialty/retina-focused commercialization.
- Genentech (Roche): Genentech markets Lucentis (ranibizumab) for wet AMD and is the originator of Avastin (bevacizumab), the IV product currently compounded off-label for ophthalmology use — the exact practice Outlook's LYTENAVA seeks to convert to an FDA-approved ophthalmic bevacizumab.
- Apellis Pharmaceuticals: Apellis markets Syfovre and Aspaveli, retinal therapeutics targeting wet AMD/geographic atrophy. As a focused retina biopharma with similar patient and HCP targets to Outlook, Apellis is a relevant direct peer in commercial-stage retinal disease.
- Novartis: Novartis markets Beovu (brolucizumab), another FDA-approved anti-VEGF therapy for wet AMD, directly competing with ONS-5010/LYTENAVA in the same intravitreal anti-VEGF category.
Broad incumbents
- Bausch + Lomb: Bausch + Lomb is a diversified ophthalmology company with a broad portfolio in retinal therapeutics, eye drops, surgical, and vision care products. It operates in the same ophthalmology commercial channel as Outlook Therapeutics.
- Alcon: Alcon is a global ophthalmology leader with surgical, vision care, and pharmaceutical offerings. While not a direct anti-VEGF competitor, it operates in the same ophthalmology prescribers, payers, and distribution channels.
- Amgen: Amgen markets Mvasi, a bevacizumab biosimilar approved for oncology indications. Its commercial bevacizumab biosimilar infrastructure represents a potential competitive or partnering reference point for Outlook's ophthalmic bevacizumab strategy.
Emerging players
- Samsung Bioepis: Samsung Bioepis develops biosimilars including bevacizumab (referenced as SB8/Aybintio). As a bevacizumab biosimilar developer, it is thematically comparable to Outlook's biosimilar/originator-bevacizumab positioning in retinal disease.
- Kodiak Sciences: Kodiak Sciences is developing next-generation anti-VEGF therapies (KSI-301 / tarcocimab) for retinal diseases including wet AMD. It targets the same wet AMD patient population with a differentiated sustained-release approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Outlook Therapeutics social profiles
Digital presenceOutlook Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Outlook Therapeutics leadership team
Management profileNumber of profiles
Profiles9 records
Outlook Therapeutics funding detail
Funding detailFunding overview
Funding rounds18 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Outlook Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Outlook Therapeutics
What does Outlook Therapeutics do?
Outlook Therapeutics develops and commercializes ONS-5010/LYTENAVA (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), an ophthalmic formulation of the anti-VEGF monoclonal antibody bevacizumab, administered via intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). The product has received European Commission and MHRA Marketing Authorization and is under FDA review in the United States.
Is Outlook Therapeutics a public or private company?
Outlook Therapeutics is a public company. It is classified as public and is currently operating.
When was Outlook Therapeutics founded?
Outlook Therapeutics was founded in 2015. It employs 11 to 50 people.
Where is Outlook Therapeutics based?
Outlook Therapeutics is headquartered in Iselin, United States, in the North America region.
How does Outlook Therapeutics make money?
Two revenue lines are on record. Product Sales (LYTENAVA) is the primary driver. The others are US Market (Pending FDA Approval).
Who are Outlook Therapeutics's main competitors?
Direct peers on record are Regeneron Pharmaceuticals, Astellas Pharma (Iveric Bio), Genentech (Roche), Apellis Pharmaceuticals and Novartis. Broad incumbents are Bausch + Lomb, Alcon and Amgen. Emerging players are Samsung Bioepis and Kodiak Sciences.
Does Outlook Therapeutics have an API?
No public API is recorded for Outlook Therapeutics.
What industry is Outlook Therapeutics in?
Outlook Therapeutics's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.